Almost two months in 2021, the market seems undecided about the next direction it will take. In fact, many investors fear that the market will be subject to a serious correction, especially because of the wide selection of richly valued stocks. It is an environment that requires a more complicated stock selection. Or perhaps it is prudent, in those moments, to seek the best to find out where the next opportunity is. And for the better, we mean the cream of the crop – the best Wall Street analysts. We removed the details of 3 stocks that the top 3 Street analysts, according to the TipRanks database, recently reserved as items to watch over the next 12 months. All three are from different sectors, but have a common feature; they are classified as strong purchases by the analyst consensus. Avalara, Inc. (AVLR) We will start with Avalara, a software company that develops cloud-based systems for international tax preparers, making it a very necessary product for any business with international customers. Avalara’s products automate business tax compliance and integrate applications for business, tax and accounting records – all the services needed to keep small and medium-sized client companies in line with local and international tax regulations. The COVID pandemic – and the social blockages and travel restrictions put in place to combat it – made it difficult for small businesses to connect with their tax professionals – and made Avalara’s products into tax automation suddenly more valuable. The company’s stock has skyrocketed since the market slowed last winter, gaining 205% from its lowest point, reached last March. These participation gains come along with the steady growth in revenue. The last reported quarter, 4Q20, showed $ 144.76 million in revenue, an increase of 13% sequentially and 34.5% year on year. Better yet, for investors looking for strength, Avalara announced in December that it will acquire the German tax software company INPOSIA. The financial terms of the agreement have not been released, but INPOSIA brings additional international tax know-how, access to Europe’s largest economy and a workforce of 50 people – who are now active for Avalara. Piper Sandler analyst Brent Bracelin is ranked first among more than 7,200 analysts and he sees the acquisition of INPOSIA as a strong move for Avalara to adjust to the European compliance landscape. “New electronic billing laws may emerge as a regulatory catalyst. Several European countries have plans to modernize the old VAT system for over 20 years with the intention of switching to digital invoicing and real-time reporting, ”said the 5-star analyst. “The acquisition of INPOSIA serves as a fundamental digital bridge for tax authorities. The acquisition of a German software company that is expected to close during 1H2021 has the potential to emerge as a new vehicle for Avalara to capitalize on all these new electronic billing laws … ”Bracelin believes that international sales are the next leap Avalara for incremental growth. In line with this perspective, the analyst classifies the stock as Overweight (ie Buy) and its target price of $ 210 implies a 26% increase for the next year. (To view Bracelin’s history, click here) Of the 11 analysts who reviewed Avalara in the past few weeks, 10 agree with Bracelin that this is a buy-in, and this split of 10 purchases for 1 wait gives the company a strong buy analyst consensus rating. Avalara’s shares are quoted at $ 166.60, and the average price target of $ 209.45 suggests it has a growth potential of approximately 26% from that level. (See analysis of AVLR shares in TipRanks) Axcelis Technologies (ACLS) Next, Axcelis, is a small capitalization company in the support sector of the semiconductor industry. Axcelis produces essential manufacturing equipment in the manufacture of semiconductor chips; specifically, Axcelis specializes in ion implantation technology essential for the chip making process. As for revenue, Axcelis reported $ 122.2 million in 4Q20, a 13.5% gain year over year and exceeding estimates by $ 3.8 million. EPS in the fourth quarter jumped from 0.29 cents a year ago to 43 cents, also beating Street’s bet by 13 cents. The beat was the latest in a long series of top performances in the final score; Axcelis has exceeded forecasts in each of the last 9 quarters. In his analysis of Axcelis, Quinn Bolton of Needham, ranked No. 2 analyst on Wall Street by TipRanks, believes that the company’s product line and sales outlook support management’s optimism. “[We] are more confident about the strength and visibility of WFE (wafer making equipment) in 2021 and now expect the company to reach $ 500 million in revenue for the entire year. We also raised our estimates to 2022 and now we believe that ACLS will reach its $ 550 million revenue target in 2022, driven by two consecutive years of growth in DRFE WFE, continued strength from mature nodes and sharing gains, ”Bolton said. These comments support Bolton’s Buy rating, and its target price of $ 44 implies a ~ 13% rise in the next 12 months. (To view Bolton’s track record, click here) Bolton’s colleagues on Wall Street broadly agree with his position on ACLS – as shown by the stock’s strong buy consensus rating with 5 unanimous reviews. The average target price, $ 46.80, is slightly more optimistic than Bolton’s and suggests a ~ 20% rise from the current share price of $ 39.02. (See ACLS stock analysis at TipRanks) TFF Pharmaceuticals (TFFP) From the semiconductor industry, we move on to the biotechnology sector, to TFF Pharmaceuticals. TFF stands for Thin Film Freezing, the patented biopharmaceutical technology platform on which the development of its innovative medicines is based. The platform allows the creation of dry powder formulations of agents that are currently administered orally, transforming them into inhalable therapies. Among a selection of next-generation versions of drugs available, the two most advanced candidates are ready to enter mid-term mid-term testing. H.C.Wainwright analyst Ram Selvaraju is ranked third among Wall Street analysts and believes they can act as a major catalyst for stocks. One candidate is TFF VORI, a dry powdered inhaled version of Voriconazole for the treatment of Invasive Pulmonary Aspergillosis (API), a dangerous fungal lung disease that in some patient populations can have a 90% mortality rate. Selvaraju expects TFF to start the development of TFF Vori Phase 2 in 1H21, and anticipates first-rate data in mid-2022. This could lead to a Phase 3 study next year or an NDA request “if the main program is determined should not be required by the FDA. ”The second candidate that is making progress is TFF Tac-Lac, a dry powder inhaled to take Tacrolimus and designed to prevent rejection of an organ transplant. A Phase 2 program may start sometime this year with the possibility of reading data in 2022. If the Phase 2 data is “sufficiently impactful,” says Selvaraju, a Phase 3 program may not be necessary. Selvaraju believes that the company could launch TFF Vori and TFF TacLac in 2024 and “achieve profitability that year”. Summing up his optimistic thesis, the 5-star analyst said: “We are convinced that there is still a potential for substantial appreciation in relation to its candidates in more advanced clinical stage and that the company’s initial stage pipeline and the applicability of the platform remain underestimated. ”. Consequently, Selvaraju values TFFP’s shares with a Buy together with a target price of $ 31. Investors can pocket a 95% gain if the analyst’s thesis materializes. (To view Selvaraju’s track record, click here) TFF has few analysts tracking its progress at the moment, but everyone is supporting its success. Based on 3 purchases, the stock has a strong purchase consensus rating. The average price target is $ 28.33 and suggests gains of ~ 78% next year. (See TFFP’s stock analysis on TipRanks) To find good ideas for stock trading with attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that gathers all information about TipRanks stock. Disclaimer: The opinions expressed in this article are exclusively those of the analysts presented. The content should be used for informational purposes only. It is very important to do your own analysis before making any investment.